EurekAlert! - Medicine and Health

Syndicate content EurekAlert! - Medicine and Health
The premier online source for science news since 1996. A service of the American Association for the Advancement of Science.
Updated: 1 day 2 hours ago

Virtual reality illuminates the power of opioid-associated memories

Sat, 2019-12-07 21:00
(American College of Neuropsychopharmacology) The brain acts differently when remembering environments associated with drug use.
Categories: News

Ancient worm reveals way to destroy toxic cells in Huntington's disease

Fri, 2019-12-06 21:00
(Monash University) Research led by a Monash University scientist has identified a highly conserved mechanism in worms and humans that controls the removal of toxic protein aggregates -- hallmarks of neurodegenerative diseases.
Categories: News

E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients

Fri, 2019-12-06 21:00
(ECOG-ACRIN Cancer Research Group) The ECOG-ACRIN Cancer Research Group today announced results from extended follow-up of patients in its randomized Phase 3 clinical trial, E1912. Previously untreated patients (aged 70 or younger) with chronic lymphocytic leukemia (CLL) who received ibrutinib-based therapy lived longer and with sustained benefit, compared to standard FCR chemoimmunotherapy. The updated analysis supports the earlier trial findings (Shanafelt, New England Journal of Medicine, August 2019).
Categories: News

Genomic features of AML in patients over age 60 can predict success of stem cell transplant

Fri, 2019-12-06 21:00
(Dana-Farber Cancer Institute) For older patients with AML, the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute will report at the ASH Annual Meeting.
Categories: News

Use of venetoclax in transplant conditioning regimen shows promise in myeloid cancers

Fri, 2019-12-06 21:00
(Dana-Farber Cancer Institute) For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies.
Categories: News